News and Trends 22 Aug 2022 BioInnovation Institute supports three start-ups The BioInnovation Institute (BII), an international commercial non-profit foundation incubating and accelerating life science research, has invested in three international start-up companies in the U.K., Germany, and Finland. The three new ventures are strategically aligned with the BII’s focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space. Each company will be funded […] August 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 17 Aug 2022 The challenges of developing radiopharmaceuticals for cancer Radiopharmaceuticals have been a relatively niche area of cancer therapy for decades. Steffen Schuster, the CEO of Germany’s ITM Group, outlines how the space is heating up, and how much nuclear medicine centers still need to grow. There are many areas in oncology research that are generating investor excitement, including immuno-oncology, DNA damage repair and […] August 17, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates A collaboration between Genmab and BioNTech to develop and commercialize immunotherapies for the treatment of cancer patients has been expanded. Under the expansion announced today (August 5), the companies will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint […] August 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Glycostem and medac sign deal on AML and MM product Glycostem Therapeutics B.V. and medac GmbH are to partner to commercialize Glycostem’s lead product, oNKord. oNKord is currently in a phase 1/2 clinical trial across 10 hospitals in five European countries. Glycostem is a Dutch clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf natural killer (NK) cells, and medac is an international pharmaceutical […] August 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Aug 2022 BioMed X Institute and Merck start new oncology research project BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA in Cancer’ (EDC) in collaboration with the Healthcare Business of Merck KGaA, Darmstadt, Germany. The main objective of this research group is to develop an atlas of extrachromosomal DNA (ecDNA) in human cancer tissues and trace back the mechanisms of […] August 1, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association Sandoz, a global pharmaceutical company working in generic and biosimilar medicines, announced this week that the US Food and Drug Administration (FDA) has accepted its biologics application (BLA) for treatment for people with multiple sclerosis (MS). The application is for a biosimilar natalizumab developed by Polpharma Biologics and includes all indications covered by the reference […] July 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Consortium awarded €4M towards platform for personalized cell therapies A company developing precision T cell therapies that treat solid tumors announced yesterday (July 21) it is leading a consortium that has been awarded a €4 million ($4.2 million) grant from Horizon Europe. The new consortium is being led by Achilles Therapeutics plc and includes CGT Catapult, Leibniz University Hannover (Hannover) as project coordinator, and […] July 22, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 13 Jul 2022 The biggest European biotech investments in June 2022 Oncology and AI-guided drug discovery firms roped in the biggest biotech investments in Europe in June 2022. The leading private rounds went to companies including ImCheck Therapeutics, MiroBio and Charm Therapeutics. In June 2022, we saw bigger private biotech investments in Europe than in May. ImCheck Therapeutics took the top spot; the firm raised an […] July 13, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 Legochem Bioscience signs agreement with Glycotope to develop cancer drug A company from South Korea has signed a research collaboration and license agreement with a German business to develop a cancer fighting drug. Seoul-based Legochem Biosciences Inc and Berlin-based Glycotope GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of […] July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, Unilever On this week’s podcast, we have three conversations: with Manfred Rüdiger, CEO of Ariceum Therapeutics; Jon Hague, Unilever’s R&D VP for homecare; and Olivier Rolland, executive director at TWB. Ambrosia and Dionymer winners at 2022 TWB Start-Up Day TWB, which sets up industrial biotechnology R&D projects and designer of innovative and sustainable solutions, announces the […] July 1, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Symrise Cosmetic Ingredients partners with evoxx technologies Symrise Cosmetic Ingredients has entered into a strategic partnership with German industrial biotech company evoxx technologies. The companies aim to develop biotechnological processes for ingredients used in beauty applications. The companies said as a result, consumers will be able to purchase beauty products with effective and responsible ingredients. Symrise said consumers today consider the ethical […] July 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Sirana Pharma and Pfizer to work on treatment for brittle bone disease German biotech company Sirana Pharma GmbH has entered into a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease, osteogenesis imperfecta (OI). Also called brittle bone disease, the condition is currently lacking approved drugs. Sirana Pharma focuses on the development of […] June 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email